Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Indomethacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 9/20 | 1.00 |
| ▸ | PTGS1 known ✓ | P23219 | 4/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 7/20 | 1.00 |
| ▸ | AKR1C2 | P52895 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | GLO1 | Q04760 | 2/20 | 1.00 |
| ▸ | AKR1C4 | P17516 | 2/20 | 1.00 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | PTGES | O14684 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indomethacin SCHEMBL29525957 | 1.00 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL29353712 | 1.00 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL9300 | 1.00 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL6356562 | 0.99 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL1817813 | 0.99 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL23632959 | 0.99 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL8352438 | 0.99 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL22472310 | 0.99 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL3860125 | 0.99 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL23391006 | 0.99 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107970220-A | A kind of Indomethacin solid disperses sustained release preparation and preparation method thereof | 浙江工业大学 | 2018-05-01 | — | — | CN | claimed |
| WO-2007110755-A1 | PROPHYLAXIS OR TREATMENT OF CARDIOVASCULAR INFLAMMATION | MEDICAL THERAPIES LIMITED (AU) | 2007-10-04 | — | — | WO | claimed |
| WO-2007026240-A1 | SUNSCREEN AND COSMETIC COMPOSITIONS FOR PROPHYLAXIS OR TREATMENT OF SKIN CANCERS | MEDICAL THERAPIES LIMITED (AU) | 2007-03-08 | — | — | WO | claimed |
| WO-2006099685-A1 | METHOD FOR THE PROPHYLAXIS OR TREATMENT OF CARCINOMAS | MEDICAL THERAPIES LIMITED (AU) | 2006-09-28 | — | — | WO | claimed |
| CN-108384031-A | A kind of preparation method and application of sustained-release hydrogel carrier material | 中南民族大学 | 2018-08-10 | — | — | CN | disclosed |
| CN-107865822-A | A kind of preparation method and application for the pharmaceutical hydrogel slow releasing carrier material for mixing mesoporous nano silicon dioxide | 中南民族大学 | 2018-04-03 | — | — | CN | disclosed |
| US-20180066004-A9 | MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2018-03-08 | — | — | US | disclosed |
| CN-105392786-B | Flavonoids and application thereof | 济州大学校产学协力团 | 2018-02-16 | — | — | CN | disclosed |
| US-9745558-B2 | VEGFR-3 ligand binding molecules and uses thereof | VEGENICS PTY LIMITED (AU) | 2017-08-29 | — | — | US | disclosed |
| US-20170190726-A9 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2017-07-06 | — | — | US | disclosed |
| US-20170087167-A1 | MODIFICATION OF DRUGS FOR INCORPORATION INTO NANOPARTICLES | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2017-03-30 | — | — | US | disclosed |
| US-20170042898-A1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2017-02-16 | — | — | US | disclosed |
| US-4350689-A | Combinations of agents which give enhanced anti-inflammatory activity | AMERICAN CYANAMID COMPANY (US) | 1982-09-21 | — | — | US | disclosed |
| US-4325949-A | ACETOXYBENZOIC ACID/O- | AMERICAN CYANAMID COMPANY (US) | 1982-04-20 | — | — | US | disclosed |
| US-4292319-A | MIXTURE WITH AN ANTIULCER AGENT | BOEHRINGER INGELHEIM GMBH (DE) | 1981-09-29 | — | — | US | disclosed |
| US-4256747-A | ANTIINFLAMMATORY AGENTS, PYRIDO/2,3B//1,4/BENZODIAZEPIN-6-ONES | BOEHRINGER INGELHEIM GMBH (DE) | 1981-03-17 | — | — | US | disclosed |
| US-4230717-A | METIAMIDE OR CEMETIDINE | LOVELACE ALAN M ADMINISTRATOR | 1980-10-28 | — | — | US | disclosed |
| US-4228161-A | INDOMETHACIN AND A SUBSTITUTED PHENYL BENZOIC ACID | MERCK & CO., INC. (US) | 1980-10-14 | — | — | US | disclosed |
| US-4154833-A | INDOMETHACIN (1-(4-CHLOROBENZOYL)-5-METHOXY-2-METHYL-1H-INDOLE-3-ACETIC ACID) WITH PIRENZEPINE (5,11-DIHYDRO-11-((4-METHYL-1-PIPERAZINYL)-ACETYL)-6H-PYRIDO(2,3 -B)(1,4)BENZODIAZEPIN-6-ONE) | BOEHRINGER INGELHEIM GMBH (DE) | 1979-05-15 | — | — | US | disclosed |
| US-4136194-A | ANTIINFLAMMATORY | SPOFA, UNITED PHARMACEUTICAL WORKS (CS) | 1979-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190726-A9 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | PTGS1, PTGES, PTGIS | PTGS2 5/4885PTGS1 1/4885AKR1C3 1333/4885 |
| US-20180066004-A9 | MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG | MT-ND4, MT-CO3, COX6A1 | PTGS2 602/4885PTGS1 661/4885AKR1C3 2874/4885 |
| US-20170087167-A1 | MODIFICATION OF DRUGS FOR INCORPORATION INTO NANOPARTICLES | NLN, PRNP, TPMT | PTGS2 38/4885PTGS1 17/4885AKR1C3 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.